Stephan Grupp, is the Director of the Cancer Immunotherapy Frontier Program, as well as Director of Translational Research in the Center for Childhood Cancer Research at the Children’s Hospital of Philadelphia (CHOP), and the Yetta Dietch Novotny Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. His primary area of clinical research is the use of engineered cell therapies in high-risk pediatric cancers, and he is leading the largest and most successful CAR T cell (engineered T cell therapy) clinical trials conducted to date (CART19/CTL019*). He is a member of the Stem Cell Transplant Section of the Division of Oncology, is Medical Director of the Stem Cell Laboratory and Program Director of the Heme-Onc Fellowship program.
Dr. Grupp graduated from the University of Cincinnati after completing the MD/PhD program with a PhD in Immunology. He completed pediatric residency at the Boston Children’s Hospital, followed by a fellowship in Pediatric Hematology/Oncology at the Dana Farber Cancer Institute and postdoctoral work in Immunology at Harvard University. He then joined the faculty at Harvard University until 1996, when he came to CHOP. His primary laboratory interest is the development of new cell therapy treatments for pediatric cancers and the molecular control of leukemic cell growth. Dr. Grupp is a reviewer for several journals and grant study sections, as well as the author of over 125 peer-reviewed journal articles, numerous abstracts and book chapters. He is also the national Chair for Stem Cell Transplantation for the Children’s Oncology Group.